Kayentis, a global provider of electronic Clinical Outcome Assessment (eCOA) solutions for patient and data collection in clinical trials, announced the completion of a 3.6 M€ growth financing round.
The round was led by Innovation Capital whose SISA fund—dedicated to private equity investments in innovative digital health companies in Europe—contributed the bulk of the financing. The historical investors, Extens, Lénapart and KCE, reinvested alongside Innovation Capital.
Kayentis has specialized in eCOA solutions for patient and data collection in clinical trials since 2009, developing a full range of services and extending its solutions portfolio to support pharmaceutical companies, biotechnology companies and CROs.
With the experience of more than 120 clinical trials in 75 countries (6,000 sites and 50,000 patients) and in a broad range of therapeutic areas, Kayentis adds value to data quality and clinical trial efficiency with innovative and intuitive solutions, and has two development priorities: Patient Engagement and Risk-based Monitoring.
The funds raised will enable Kayentis to further accelerate its growth internationally through increased investments in sales, marketing and R&D, and position the company as a leading global provider of eCOA solutions.
“This round of financing validates our development model and our significant growth prospects. It also provides Kayentis with the means to continue improving our technological platform and value-added services to better serve our clients worldwide. I am particularly pleased to welcome Innovation Capital as a new investor or and business partner to accompany us in this new and exciting growth phase for Kayentis. I also thank the existing investors for their continuous support,” said Guillaume Juge, CEO of Kayentis.
“We are delighted to partner with Kayentis and its experienced management team,” said Franck Noiret, general partner of Innovation Capital. “This is the 7th investment of our SISA fund dedicated to the financing of innovative digital health companies in Europe. Kayentis has had an impressive track record in the last few years, and we are confident it will continue to grow fast.”